Investigational Drug Information for Emricasan
✉ Email this page to a colleague
What is the drug development status for Emricasan?
Emricasan is an investigational drug.
There have been 15 clinical trials for Emricasan.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2013.
The most common disease conditions in clinical trials are Fibrosis, Liver Cirrhosis, and Fatty Liver. The leading clinical trial sponsors are Conatus Pharmaceuticals Inc., Histogen, and University of Alberta.
Summary for Emricasan
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 496 |
| WIPO Patent Applications | 333 |
| Japanese Patent Applications | 138 |
| Clinical Trial Progress | Phase 2 (2013-07-01) |
| Vendors | 59 |
Recent Clinical Trials for Emricasan
| Title | Sponsor | Phase |
|---|---|---|
| Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19 | Histogen | Phase 1 |
| Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis | Conatus Pharmaceuticals Inc. | Phase 2 |
| Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension | Conatus Pharmaceuticals Inc. | Phase 2 |
Clinical Trial Summary for Emricasan
Top disease conditions for Emricasan
Top clinical trial sponsors for Emricasan
US Patents for Emricasan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
